Held by: VXF | Scroll to Statements |
Index | - | P/E | - | EPS (ttm) | -19.18 | Insider Own | 1.74% | Shs Outstand | 2.10M | Perf Week | -16.53% |
Market Cap | 4.24M | Forward P/E | - | EPS next Y | -2.71 | Insider Trans | 0.00% | Shs Float | 2.06M | Perf Month | -14.04% |
Income | -27.63M | PEG | - | EPS next Q | -2.30 | Inst Own | 6.83% | Short Float | 2.29% | Perf Quarter | -33.11% |
Sales | 0.00M | P/S | - | EPS this Y | 74.73% | Inst Trans | 28.32% | Short Ratio | 0.45 | Perf Half Y | -76.92% |
Book/sh | 4.55 | P/B | 0.44 | EPS next Y | 52.46% | ROA | -153.97% | Short Interest | 0.05M | Perf Year | -93.61% |
Cash/sh | 3.91 | P/C | 0.52 | EPS next 5Y | - | ROE | -202.83% | 52W Range | 2.01 - 42.00 | Perf YTD | -78.04% |
Dividend Est. | - | P/FCF | - | EPS past 5Y | 8.89% | ROI | -315.49% | 52W High | -95.19% | Beta | -0.51 |
Dividend TTM | - | Quick Ratio | 2.42 | Sales past 5Y | 0.00% | Gross Margin | - | 52W Low | 0.50% | ATR (14) | 0.27 |
Dividend Ex-Date | - | Current Ratio | 2.42 | EPS Y/Y TTM | 14.61% | Oper. Margin | 0.00% | RSI (14) | 37.21 | Volatility | 9.10% 11.96% |
Employees | 26 | Debt/Eq | 0.00 | Sales Y/Y TTM | - | Profit Margin | - | Recom | 1.00 | Target Price | 10.00 |
Option/Short | No / Yes | LT Debt/Eq | 0.00 | EPS Q/Q | 50.43% | Payout | - | Rel Volume | 0.30 | Prev Close | 2.05 |
Sales Surprise | - | EPS Surprise | 0.00% | Sales Q/Q | - | Earnings | May 29 | Avg Volume | 105.70K | Price | 2.02 |
SMA20 | -18.33% | SMA50 | -16.56% | SMA200 | -73.43% | Trades | Volume | 32,106 | Change | -1.46% |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions withourpremium features. Real-time quotes, advancedvisualizations, backtesting, and much more.
Learn more about FINVIZ*Elite